Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Sales of Novo Nordisk‘s blockbuster Wegovy weight loss drug surged in the second quarter, the company said in its latest report, days after cutting its full-year guidance and announcing a new CEO.
Overall revenues rose 13% year-on-year at constant exchange rates to 76.86 billion Danish kroner ($11.92 billion) in the three months to the end of June, just ahead of the 76.6 billion Danish kroner forecast.
Sales of its blockbuster Wegovy obesity drug rose 67% over the period to 19.53 billion Danish kroner, slightly below the 20 billion Danish kroner analysts had forecast.
Quarterly net profit came in at 26.5 billion Danish kroner, versus 26.6 billion Danish kroner analysts expected.
This is a developing story. Please check back for updates.
